Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Salarius Pharmaceuticals Inc
Research & Development
Salarius Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
|
Research & Development
-$429k
|
CAGR 3-Years
69%
|
CAGR 5-Years
41%
|
CAGR 10-Years
28%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Salarius Pharmaceuticals Inc
Glance View
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The company is headquartered in Houston, Texas and currently employs 16 full-time employees. The company went IPO on 2015-01-29. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The firm is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.
See Also
What is Salarius Pharmaceuticals Inc's Research & Development?
Research & Development
-429k
USD
Based on the financial report for Sep 30, 2025, Salarius Pharmaceuticals Inc's Research & Development amounts to -429k USD.
What is Salarius Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
28%
Over the last year, the Research & Development growth was 34%. The average annual Research & Development growth rates for Salarius Pharmaceuticals Inc have been 69% over the past three years , 41% over the past five years , and 28% over the past ten years .
